Frontlight ResearchEarly access
CompletedNo phase
Efficacy and Safety of the Self-expanding Intracranial Stent (Tonbridge) for Endovascular Treatment of Intracranial Aneurysms
Key facts
- Who runs it
- Ton-Bridge Medical Tech. Co., Ltd
- Where
- China14 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 204 people enrolled
- Started
- 14 Feb 2023
- Ended
- 13 Dec 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Self-expanding Intracranial Stent (Tonbridge)
- LVIS and LVIS Jr. (MicroVention)
- Record updated
- 2 January 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Age 18 to 80 years, any gender
- Diagnosed as intracranial aneurysm and the subject is assessed as suitable for stent-assisted coiling
- Subject or guardian is able to understand the purpose of study, shows sufficient compliance with the study protocol and provides a signed informed consent form
Who cannot take part
- Aneurysm rupture within 30 days before enrollment
- Heart, lung, liver and renal failure or other severe diseases (intracranial tumor, systemic infection, disseminated intravascular coagulation, myocardial infarction within 12 months before enrollment, history of severe psychosis, severe stenosis or occlusion of cerebral feeding artery, etc.)
- Major surgery within 30 days before enrollment;
- Known coagulation dysfunction or contraindication to anticoagulant and antiplatelet therapy
- Subject has participated in other drug or medical device clinical trials within 1 month before signing informed consent
- Diagnosed as blood blister-like aneurysm, pseudoaneurysm, infected aneurysm, or aneurysm related to arteriovenous malformations
- Conditions that are not appropriate for stent delivery and deployment judged by investigators (severe stenosis of parent artery, severe tortuosity of parent artery, stent failing to reach the lesion, stent in the target lesion of parent artery, etc.)
- Known allergy to nickel-titanium alloy metal materials
- Other conditions judged by the investigators as unsuitable for enrollment
- Modified Rankin Scale (mRS) score ≥3
- Life expectancy <12 months
- Pregnant or breastfeeding women
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to assess the efficacy and safety of Self-expanding Intracranial Stent (Tonbridge), by comparing the data obtained from Self-expanding Intracranial Stent (Zhuhai Tonbridge Medical Tech. Co., Ltd.) and LVIS/LVIS Jr. (MicroVention Europe SARL) for endovascular treatment of intracranial aneurysms.
The 2 groups in the trial
- experimental groupTreatment being tested
Self-expanding Intracranial Stent (Tonbridge)
Treatment: Self-expanding Intracranial Stent (Tonbridge)
- control groupExisting treatment, for comparison
LVIS and LVIS Jr. (MicroVention)
Treatment: LVIS and LVIS Jr. (MicroVention)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of the Self-expanding Intracranial Stent (Tonbridge) for Endovascular Treatment of Intracranial Aneurysms: A Prospective, Multi-center, Randomized, Open, Parallel Positive Controlled, Non-inferiority Trial
- Record updated
- 2 January 2026